vimarsana.com

Latest Breaking News On - பல்கலைக்கழகம் பெல்ஜியம் - Page 1 : vimarsana.com

Phase I clinical study evaluates safety and pharmacokinetics of ExeVir s COVID-19 neutralizing antibody

ExeVir, which is developing single domain antibody therapies providing broad protection against viral infections, today announces that the first subjects have been dosed in a Phase I clinical study of XVR011, its llama-derived antibody for the treatment and prevention of COVID-19.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.